Neurodegenerative Disorder Therapeutics Sector Forecast Shows Robust Momentum, Climbing to $34.13 Billion With 9.6% CAGR
Uncover key drivers, emerging technologies, and competitive movements shaping the neurodegenerative disorder therapeutics market from 2026–2035 with trusted insights from The Business Research Company
What are the forecasted starting (2026) and ending (2030) market sizes for the Neurodegenerative Disorder Therapeutics Market?
The neurodegenerative disorder therapeutics market size has experienced robust expansion over the past few years. This market is projected to expand from $21.66 billion in 2025 to $23.65 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.2%. Historically, this growth has been driven by factors such as the increasing prevalence of neurodegenerative disorders, a burgeoning aging population, the presence of limited treatment options, heightened awareness regarding early diagnosis, and the development of hospital and neurology care infrastructure.
The neurodegenerative disorder therapeutics market is poised for substantial expansion in the coming years. This market is projected to reach $34.13 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.6%. This anticipated growth during the forecast period is attributable to the development of gene therapies, progress in monoclonal antibody treatments, the integration of AI-based diagnostics and monitoring, increased investment in clinical research and trials, and the expansion of personalized medicine and targeted therapeutics. Significant trends over the forecast period are expected to include the increasing adoption of neuroprotective and neurorestorative therapies, a heightened focus on symptom management and patient-centric care, a rise in clinical trials for novel neurodegenerative drugs, the broadening of personalized and targeted therapeutic approaches, and the incorporation of home care and remote monitoring solutions.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2818&type=smp
What Drivers Are Supporting Technological Adoption In The Neurodegenerative Disorder Therapeutics Market?
Enhanced financial commitment to research and development (R&D) for neurodegenerative disorder treatments is projected to fuel the expansion of the neurodegenerative disorder therapeutics market in the future. Governments and various organizations initiate these R&D investments in neurodegenerative disorders due to several pressing factors, such as the rising incidence, considerable unmet healthcare demands, economic impacts, and worldwide health endeavors, among others. For instance, in March 2023, the Government of Canada, a Canada-based federal administration, disclosed a $38.3 million investment in 2023, dedicated to boosting research into neurodegenerative diseases. Consequently, sustained investment in R&D for neurodegenerative disorder therapeutics is anticipated to continuously spur the growth of the neurodegenerative disorder therapeutics market throughout the forecast timeframe.
Which Segments Are Contributing To The Growth Of The Neurodegenerative Disorder Therapeutics Market?
The neurodegenerative disorder therapeutics market covered in this report is segmented –
1) By Indication Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Other Indication Types
2) By Drug Type: N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, Other Drug Types
3) By Distribution: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Parkinson’s Disease: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
2) By Alzheimer’s Disease: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Anti-Amyloid Monoclonal Antibodies
3) By Multiple Sclerosis: Immunomodulators, Immunosuppressants, Corticosteroids
4) By Huntington’s Disease: Tetrabenazine, Antipsychotic Medications
5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments, Frontotemporal Dementia Treatments, Prion Disease Treatments
Which Trends Are Expected To Influence The Neurodegenerative Disorder Therapeutics Market In The Upcoming Years?
Major companies in the neurodegenerative disorder therapeutics market are concentrating on developing innovative treatment options, particularly prodrug formulations, to enhance the bioavailability, efficacy, and safety profiles of Parkinson’s disease therapies. Prodrugs are inactive compounds that are metabolically transformed into active drugs within the body, enabling controlled and sustained delivery of therapeutic agents. For instance, in January 2024, AbbVie Inc., a US-based biopharmaceutical company, introduced PRODUODOPA (foslevodopa or foscarbidopa) in the European Union for individuals living with advanced Parkinson’s disease. This therapy utilizes a soluble prodrug combination to provide continuous levodopa delivery, aiming to diminish motor fluctuations and improve patients’ quality of life. This launch represents a significant advancement in managing advanced Parkinson’s disease by offering an alternative to intermittent oral dosing and improving treatment adherence.
Who Are The Major Companies Operating In The Neurodegenerative Disorder Therapeutics Market?
Major companies operating in the neurodegenerative disorder therapeutics market are Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Bayer Schering Pharma AG, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Eisai Co. Ltd., Bristol Myers Squibb Company, Amylyx Pharmaceuticals Inc., Genentech Inc., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.
Access The Complete Report For Deeper Market Insights:
Which Region Is Anticipated To See The Fastest Growth In The Neurodegenerative Disorder Therapeutics Market?
North America was the largest region in the global neurodegenerative disorder therapeutics market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Neurodegenerative Disorder Therapeutics Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=2818&type=smp
Browse Through More Reports Similar to the Global Neurodegenerative Disorder Therapeutics Market 2026, By The Business Research Company
Neurology Devices Market Report 2026
https://www.thebusinessresearchcompany.com/report/neurology-devices-global-market-report
Interventional Neurology Devices And Equipment Market Report 2026
Neurosurgery Devices And Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
